Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001
The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: 330 Year: 2004
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006
Sublingual monomeric allergoid immunotherapy improves airway inflammation, airway hyperresponsiveness and clinical symptoms in allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006
Omalizumab in the treatment of perennial allergic rhinitis Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002
Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Comparison of late allergic inflammatory responses in asthma and rhinitis after nasal and bronchial allergen challenge Source: Eur Respir J 2001; 18: Suppl. 33, 269s Year: 2001
The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Levocetirizine and montelukast in the treatment of seasonal allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 137s Year: 2005
Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006
A single nasal allergen challenge increases induced sputum inflammatory parameters in non-asthmatic patients with seasonal allergic rhinitis Source: Eur Respir J 2001; 18: Suppl. 33, 163s Year: 2001
Intranasal and inhaled corticosteroids in allergic rhinitis and asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004
Budesonide nasal spray alone or in combination with cetirizine in patients with severe seasonal allergic rhinitis and asthma Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002
The influence of the allergen-specific immunotherapy (ASIT) against the backdrop of an immunomodulator in patients suffering from seasonal allergic rhinitis (SAR) on the level of cytokines, IgE and IgG. Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020